A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy.

  • Age-Related Macular Degeneration
Trial Status:

Active, not recruiting

This trial runs in
  • Asheville
  • Austin
  • Dallas
  • Denver
  • Los Angeles
  • Melbourne
  • Mountain View
  • Nashville
  • Oak Forest
  • Reno
  • Royal Oak
  • Sacramento
  • Santa Maria
Trial Identifier:

NCT04615325 GR42163

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multicenter study will investigate the safety, tolerability, pharmacokinetics, and immunogenicity of RO7303359 following single Intravitreal (ITV) injection in participants with geographic atrophy (GA) secondary to age related macular degeneration (AMD). The participants will receive ITV injections of RO7303359 in the single ascending dose stage and maximum tolerated dose (MTD) or maximum tested dose (MTeD) of RO7303359 will be administered in the expansion stage.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT04615325 , GR42163 Trial Identifier
      RO7303359 Treatments
      Geographic Atrophy Condition
      Official Title

      A Phase 1a, Multicenter, Open Label, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Patients With Geographic Atrophy Secondary to Age Related Macular Degeneration

      Eligibility Criteria

      All Gender
      ≥50 Years Age
      No Healthy Volunteers
      Inclusion Criteria

      Ocular Inclusion Criteria Study Eye:

      • Well-demarcated area of GA secondary to AMD in the absence of choroidal neovascularization (CNV)
      • GA area must be >= 0.5 disc area (1.25 mm2)
      Exclusion Criteria

      Ocular Exclusion Criteria, Study eye:

      • GA due to causes other than AMD
      • History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
      • Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, or proliferative diabetic retinopathy
      • Prior treatment with Visudyne, external beam radiation therapy (for intraocular conditions), or transpupillary thermotherapy

      Ocular Exclusion Criteria, Both eyes:

      • Evidence of prior or active CNV
      • Previous participation in interventional clinical trials for GA or dry AMD, except for vitamins and minerals, irrespective of the route of administration (i.e. ocular or systemic) within the last 6 months

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now